retatrutide dosage phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Phase 2 Trial of Retatrutide

Bottom line: GLP-1 patches may contain recognisable ingredients, but there is currently no strong evidence that those ingredients are absorbed through the skin in amounts sufficient to support the effects claimed

However, not all of the data is supportive and metformin, as shown in C

Please confirm before continuing

In the article's clinical criteria table, prior interventions means documented structured lifestyle programs covering diet, exercise, and behavioral therapy that were attempted before GLP-1 therapy is considered

Vilsbll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrges JP et al (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes